

# 26L-pm03

Drug-protein interaction: Ultra Accelerated Quantum Chemical Molecular Dynamics study

○Kamlesh SAHU<sup>1</sup>, 鈴木 愛<sup>2</sup>, Riadh SAHNOUN<sup>1</sup>, 古山 通久<sup>4</sup>, 坪井 秀行<sup>1</sup>,  
畠山 望<sup>1</sup>, 遠藤 明<sup>1</sup>, 高羽 洋充<sup>1</sup>, Carlos DEL CARPIO<sup>1</sup>, 久保 百司<sup>1</sup>,  
西島 和三<sup>2,3</sup>, 宮本 明<sup>1,2</sup> (1東北大院工, 2東北大未来セ, 3持田製薬, 4九州大稲盛セ)

**【Introduction】** Protein-ligand interactions play a central role in biochemistry and one of the interactions of this kind is that between a pharmaceutically important chemical moiety and its target enzyme. The objective of current work was to study drug-protein interactions using ultra accelerated quantum chemical molecular dynamics method (UAQCMD). For the first time, the drug protein interactions are studied using this method.

**【 Method 】** We have used UAQCMD method. We derived potentials from quantum chemical calculations and used for MD simulations.

**【Result and discussion】** Fig. 1 shows the methotrexate (MTX) in binding site of dihydrofolate reductase (DHFR) enzyme where Asp27 is the closest amino acid

whose oxygen atoms interact with hydrogen of MTX. Oxygen atoms a and b from Asp27 were found to be interacting with hydrogen atom of MTX and this was confirmed by QC calculation in which a bond population of 0.4 was obtained for oxygen a and b with MTX-hydrogen. The comparatively lesser charges of  $-0.422$  and  $-0.514$  on oxygen a and b respectively indicate the shift of electron pairs towards hydrogen.




Fig.1 Methotrexate in the binding site of DHFR